Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: Results from a subgroup of the PREDICTIVE™ study

International Journal of Clinical Practice

Volumn 63, Issue 3, 2009, Pages 425-432

  Yenigun, M ^a   Honka, M ^b  

^a Education Hospital   (Turkey)

^b UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCEMIC INDEX; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT CHANGE;

ADULT; AGED; COHORT STUDIES; DIABETES MELLITUS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 59349118528     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01973.x     Document Type: Article

References (42)

1. Nathan DM, Cleary PA, Backlund JY et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 353 : 2643 53.
2. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 321 : 405 12.
3. The Diabetes Control Complications Trial Research Group (DCCT). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329 : 977 86.
4. The Diabetes Control Complications Trial Research Group (DCCT). Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997 46 : 271 86.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 53.
6. Starke AA, Heinemann L, Hohmann A, Berger M. The action profiles of human NPH insulin preparations. Diabet Med 1989 6 : 239 44.
7. Kølendorf K, Bojsen J, Deckert T. Clinical factors influencing the absorption of 125I-NPH insulin in diabetic patients. Horm Metab Res 1983 15 : 274 8.
8. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999 22 (Suppl. 2 B109 13.
9. Bolli GB, Owens DR. Insulin glargine. Lancet 2000 356 : 443 5.
10. Peterson GE. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Curr Med Res Opin 2006 22 : 2613 9.
11. Gerich JE. Insulin glargine: long-acting basal insulin analog for improved metabolic control. Curr Med Res Opin 2004 20 : 31 7.
12. Yki-Jarvinen H, Dressler A, Ziemen M, HOE 901/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000 23 : 1130 6.
13. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003 26 : 3080 6.
14. Heise T, Nosek L, Ronn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004 53 : 1614 20.
15. Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005 28 : 1107 12.
16. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007 9 : 648 59.
17. Russell-Jones D, Simpson R, Hylleberg B et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004 26 : 724 36.
18. Kølendorf K, Ross GP, Pavlic-Renar I et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabet Med 2006 23 : 729 35.
19. Hermansen K, Fontaine P, Kukolja KK et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004 47 : 622 9.
20. Haak T, Tiengo A, Draeger E et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005 7 : 56 64.
21. Raslová K, Bogoev M, Raz I et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004 66 : 193 201. Erratum in: Diabetes Res Clin Pract 2006; 72(1): 112.
22. Vague P, Selam JL, Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003 26 : 590 6.
23. Hermansen K, Davies M, Derezinski T et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006 29 : 1269 74.
24. De Leeuw I, Vague P, Selam JL et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005 7 : 73 82.
25. Dornhorst A, Luddeke HJ, Sreenan S et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract 2007 61 : 523 8.
26. IDF European Diabetes Policy Group. A Desktop Guide to Type 1 (Insulin-Dependent) Diabetes. Brussels : International Diabetes Federation, 1998.
27. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels : International Diabetes Federation, 2005. http://www.idf.org/home/ index.cfm?node=1457 (accessed February 2008).
28. Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care 2000 23 : 157 62.
29. Hermansen K, Madsbad S, Perrild H et al. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001 24 : 296 301.
30. Bartley PC, Bogoev M, Larsen J, Philotheous A. Long-term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008 25 : 442 9.
31. Pieber TR, Treichel HC, Hompesch B et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med 2007 24 : 635 42.
32. Havelund S, Plum A, Ribel U et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004 21 : 1498 504.
33. Home P, Bartley P, Russell-Jones D et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes; a randomised clinical trial. Diabetes Care 2004 27 : 1081 7.
34. Philis-Tsimikas A, Charpentier G, Clauson P et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006 28 : 1569 81. Erratum in: Clin Ther 2006; 28: 10967.
35. Robertson KJ, Schoenle E, Gucev Z et al. Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med 2007 24 : 27 34.
36. Jacqueminet S, Masseboeuf N, Rolland M et al. Limitations of the so-called 'intensified' insulin therapy in type 1 diabetes mellitus. Diabetes Metab 2005 2 : 4S45 50.
37. Rosenstock J, Davies M, Home PD et al. Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycaemic control comparable to insulin glargine with less weight gain. Diabetes 2006 55 (Suppl. 1 A132.
38. Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005 22 : 850 7.
39. Raslova K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig 2007 27 : 279 85.
40. Polonsky WH, Anderson BJ, Lohrer PA et al. Insulin omission in women with IDDM. Diabetes Care 1994 17 : 1178 85.
41. Bryden KS, Neil A, Mayou RA et al. Eating habits, body weight, and insulin misuse. A longitudinal study of teenagers and young adults with type 1 diabetes. Diabetes Care 1999 22 : 1956 60.
42. Fakoury W, Lockhart I, Kotchie RW, Aagren M, LeReun C. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type 2 diabetes. Pharmacology 2008 82 : 156 63.